Cargando…

Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects

Multiple myeloma (MM) is a hematologic malignancy characterized by excessive clonal proliferation of plasma cells. The treatment of multiple myeloma presents a variety of unique challenges due to the complex molecular pathophysiology and incurable status of the disease at this time. Given that MM is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lassiter, Grace, Bergeron, Cole, Guedry, Ryan, Cucarola, Julia, Kaye, Adam M., Cornett, Elyse M., Kaye, Alan D., Varrassi, Giustino, Viswanath, Omar, Urits, Ivan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924384/ https://www.ncbi.nlm.nih.gov/pubmed/33494319 http://dx.doi.org/10.3390/curroncol28010063

Ejemplares similares

Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
por: Lassiter, Grace, et al.
Publicado: (2020)

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022)

The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
por: Becnel, Melody R., et al.
Publicado: (2020)

Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
por: Offidani, Massimo, et al.
Publicado: (2021)

Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma
por: Gil-Sierra, Manuel David, et al.
Publicado: (2022)

A Comprehensive Update of the Current Understanding of Chronic Fatigue Syndrome
por: Noor, Nazir, et al.
Publicado: (2021)

Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin
por: Springer, Carsten, et al.
Publicado: (2023)

Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
por: Wahab, Ahsan, et al.
Publicado: (2021)

Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin
por: Lu, Rebecca, et al.
Publicado: (2023)

P20: POLYCENTRIC “REAL LIFE” STUDY OF BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Iula, R, et al.
Publicado: (2022)

Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma
por: Neupane, Karun, et al.
Publicado: (2021)

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
por: Lonial, Sagar, et al.
Publicado: (2021)

Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma
por: Popat, Rakesh, et al.
Publicado: (2023)

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

Belantamab mafodotin associated corneal microcyst-like epithelial changes
por: Chuang, Katherine, et al.
Publicado: (2022)

Surgical and Non-surgical Treatment Options for Piriformis Syndrome: A Literature Review
por: Vij, Neeraj, et al.
Publicado: (2021)

Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)
por: Berger, Amnon A., et al.
Publicado: (2021)

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
por: Rathi, Chetan, et al.
Publicado: (2021)

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
por: Vaxman, I., et al.
Publicado: (2021)

Exposure–Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma
por: Ferron‐Brady, Geraldine, et al.
Publicado: (2021)

An Update on Treatment Modalities for Ulnar Nerve Entrapment: A Literature Review
por: Vij, Neeraj, et al.
Publicado: (2020)

Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences
por: Morè, Sonia, et al.
Publicado: (2023)

Peripheral Neuromodulation for the Management of Headache
por: Urits, Ivan, et al.
Publicado: (2020)

Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States
por: Shah, Anshul, et al.
Publicado: (2021)

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
por: Joseph, Nisha S, et al.
Publicado: (2021)

Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma
por: Ketchum, Emily Behren, et al.
Publicado: (2022)

Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience
por: Iula, Rossella, et al.
Publicado: (2022)

Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
por: Shragai, Tamir, et al.
Publicado: (2022)

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain
por: de la Rubia, Javier, et al.
Publicado: (2023)

Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma
por: Collins, Jon, et al.
Publicado: (2023)

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

PB2114: BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE
por: Hultcrantz, Malin, et al.
Publicado: (2023)

Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11
por: Iida, Shinsuke, et al.
Publicado: (2023)

Utilization of Intravenous Lidocaine Infusion for the Treatment of Refractory Chronic Pain
por: Tully, Janell, et al.
Publicado: (2021)

Intraoperative Hypotension Increased Risk in the Oncological Patient
por: Mohammad Shehata, Islam, et al.
Publicado: (2021)

Occupational burnout syndrome and post-traumatic stress among healthcare professionals during the novel coronavirus disease 2019 (COVID-19) pandemic
por: Raudenská, Jaroslava, et al.
Publicado: (2020)

Efficacy of Acupuncture in the Treatment of Chronic Abdominal Pain
por: Berger, Amnon A., et al.
Publicado: (2021)

Efficacy of Dry Needling and Acupuncture in the Treatment of Neck Pain
por: Berger, Amnon A., et al.
Publicado: (2021)

Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review
por: Berger, Amnon A., et al.
Publicado: (2020)

Utilization of Magnesium for the Treatment of Chronic Pain
por: Urits, Ivan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_549veobe0dmmeg24hia7i7105v